Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: the EMPEROR Program | JACC episode artwork

EPISODE · May 5, 2025 · 9 MIN

Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: the EMPEROR Program | JACC

from JACC This Week

In this podcast, Dr. Valentin Fuster explores a study on the effects of SGLT2 inhibitors, like empagliflozin, on erythropoiesis and iron mobilization in heart failure patients. The research reveals how these drugs activate key metabolic pathways, potentially enhancing iron utilization and improving clinical outcomes, with significant implications for treatment in heart failure and chronic kidney disease.

Episode metadata supplied by the publisher feed · Published May 5, 2025

Embed this episode

Ready to play

Effect of Empagliflozin on the Mechanisms Driving Erythropoiesis and Iron Mobilization in Patients With Heart Failure: the EMPEROR Program | JACC

0:00 9:37

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of JACC This Week?

This episode is 9 minutes long.

When was this JACC This Week episode published?

This episode was published on May 5, 2025.

Can I download this JACC This Week episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!